Gomisin A and metformin co-treatment attenuates diabetic nephropathy and cardiovascular dysfunction by modulating the AGE/RAGE pathway in a diabetic rat model - PubMed
7 days ago
- #Metformin
- #Diabetic nephropathy
- #Gomisin A
- Diabetic nephropathy (DN) is a severe complication of type 2 diabetes mellitus (T2DM), often accompanied by cardiovascular disease (CVD) and chronic kidney disease (CKD).
- Current therapeutic options for DN and CVD are limited and often produce significant adverse effects.
- Gomisin A, alone and in combination with metformin, was evaluated for renal and cardioprotective effects in a diabetic rat model.
- Co-treatment with Gomisin A (20 mg/kg) and metformin significantly improved glycemic control, renal function, and β-cell integrity.
- The combination therapy reduced renal hypertrophy, inflammation, and oxidative stress markers (serum creatinine, urea, phosphorus, LDH, MDA).
- The AGE/RAGE pathway was modulated, leading to downregulation of NF-κB, proinflammatory cytokines, and TGF-β in renal tissues.
- Cardiac protective effects included inhibition of myocardial thickening and hypertrophy.
- Gomisin A and metformin synergistically mitigate DN and CVD progression, suggesting Gomisin A as a nutraceutical adjunct to anti-diabetic treatments.